Search results
Showing 6886 to 6900 of 8314 results
Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
This guidance has been updated and replaced by NICE interventional procedures guidance 762.
This guidance has been updated and replaced by NICE interventional procedures guidance 794.
This guidance has been updated and replaced by NICE interventional procedures guidance 802.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)
Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedures guidance 715.
Percutaneous intradiscal radiofrequency thermocoagulation for lower back pain (IPG83)
Interventional procedures, IPG83 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedure guidance 545.
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.
Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)
This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.
Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)
April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.
November 2024: This evidence summary has been withdrawn because licensed products are now available.
Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)
This advice has been updated and replaced by NICE medical technologies guidance 50.
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.